Welcome to our dedicated page for Precipio SEC filings (Ticker: PRPO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Precipio, Inc. filings document the public-company disclosures of a specialty cancer diagnostics issuer with Pathology Services and Products operations. Its Form 8-K reports include Regulation FD updates for shareholder calls and investor presentations, furnished financial results, and material-event disclosures related to corporate communications and operating performance.
The company’s proxy materials describe annual meeting procedures, stockholder voting matters, governance, and access to annual reporting materials. Other filings document capital-structure matters, including common stock activity and the termination of an at-the-market sales agreement, alongside formal exhibits and disclosures tied to Precipio’s diagnostics business and shareholder communications.
Precipio, Inc. (PRPO) reported Q3 2025 results. Net sales were $6,767 thousand, up from $5,209 thousand a year ago, driven by higher diagnostic testing revenue from Medicare and third-party payers. Gross profit rose to $3,005 thousand. Operating loss narrowed to $61 thousand and net loss improved to $79 thousand from $626 thousand.
For the nine months, net sales were $17,350 thousand versus $13,082 thousand, with net loss improving to $889 thousand from $3,925 thousand. Cash at quarter-end was $2,305 thousand, aided by $1,260 thousand of warrant exercise proceeds and $319 thousand provided by operating activities. The company disclosed “substantial doubt” about its ability to continue as a going concern over the next twelve months. As of November 11, 2025, common shares outstanding were 1,752,007.
Precipio, Inc. (PRPO) announced it will host a Q3‑2025 Shareholder Update Call on November 17, 2025 at 5:00 PM ET. The call will include updates on all of the company’s current core businesses.
The company furnished a press release as Exhibit 99.1. The information, including the exhibit, is being furnished and is not deemed filed under the Exchange Act.
Precipio (PRPO) director Kathleen D. LaPorte reported acquiring 711 shares of common stock on October 15, 2025 at $17.58 per share. The grant was issued in lieu of cash compensation for service on the Board of Directors for Q3-25.
After this transaction, LaPorte directly owns 6,862 shares of Precipio common stock.
Precipio (PRPO): A company director reported acquiring 597 shares of common stock on October 15, 2025 at $17.58 per share. The shares were granted as equity in lieu of cash compensation for service on the Board for Q3-25.
Following the transaction, the reporting person beneficially owns 15,247 shares, held directly.
Precipio, Inc. (PRPO) reported an insider transaction by a director. On 10/15/2025, the director acquired 568 shares of common stock in a transaction coded “A,” reflecting a grant in lieu of cash compensation for Board service for Q3‑25. The filing lists a price of $17.58.
Following this grant, the director’s beneficial ownership stands at 15,708 shares, held directly. This is a routine equity compensation event and does not indicate a public offering or company-level capital raise.
Precipio, Inc. (PRPO) reported an insider stock transaction by a director. On October 15, 2025, the director acquired 746 shares of common stock at $17.58 per share. The grant was issued as consideration in lieu of cash compensation for service on the Board of Directors for Q3-25.
Following this transaction, the director beneficially owns 53,572 shares, held directly.
Leviticus Partners LP reports beneficial ownership of 130,000 shares of Precipio, Inc. common stock, representing 8.0% of the class. The filing states the shares are held with sole voting and dispositive power and were acquired and are held in the ordinary course of business, not for the purpose of changing control of the issuer. The filing is signed by Adam M Hutt as Managing Member and dated 09/22/2025. No group affiliations, subsidiaries, or additional arrangements are disclosed.
Kathleen LaPorte, a director of Precipio, Inc. (PRPO), reported the sale of 6,152 shares of the issuer's common stock on 09/08/2025 at a weighted average price of $20.06 per share. After the reported disposals, she beneficially owned 6,151 shares. The shares were originally granted to Ms. LaPorte on 04/15/2024 as consideration in lieu of cash for board service covering Q1 2023 through Q1 2024; that grant was approved by the board under Rule 16b-3 and is exempt from Section 16(b). The Form 4 is signed by Ms. LaPorte on 09/10/2025. The filing notes the shares were sold in multiple transactions at prices ranging from $20.00 to $20.50.
Form 144 notice for Precipio, Inc. (PRPO): A holder plans to sell 6,152 shares of Common stock through Morgan Stanley Smith Barney, with an aggregate market value of $123,384.51. The shares represent part of 1,619,584 shares outstanding and the proposed approximate sale date is 09/08/2025.
The shares were acquired on 04/15/2024 as board compensation and paid as compensation. The filer reports no sales in the past three months and certifies no undisclosed material information.
Precipio, Inc. filed a current report to disclose that it has terminated its Sales Agreement with A.G.P./Alliance Global Partners covering an at-the-market offering program for its common stock, effective September 2, 2025. After this termination, Precipio can no longer sell additional shares under that agreement.
From April 14, 2023 through September 2, 2025, the company sold 11,847 shares of common stock under the program, generating net proceeds of approximately $0.1 million after commissions and offering expenses. Precipio also issued a press release announcing the termination.